Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua D Noe

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Inflammatory Bowel Diseases|February 21, 2018
Moving On: Transition Readiness in Adolescents and Young Adults With IBDAmitha Prasad Gumidyala, Rachel N Greenley, Jill M Plevinsky, et al.
Inflammatory Bowel Diseases|September 18, 2020
Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's DiseaseRuben J Colman, Yi-Ting Tsai, Kimberly Jackson, et al.
Clinical Pharmacology and Therapeutics|December 23, 2020
Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's DiseaseYe Xiong, Tomoyuki Mizuno, Ruben Colman, et al.
Journal of Pediatric Gastroenterology and Nutrition|June 22, 2023
Exome Sequencing Implicates DGKZ , ESRRA , and GXYLT1 for Modulating Granuloma Formation in Crohn DiseaseR Alan Harris, Allyson H Bush, Todd N Eagar, et al.
Alimentary Pharmacology & Therapeutics|December 22, 2021
Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's diseaseRuben J Colman, Ye Xiong, Tomoyuki Mizuno, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2022
Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearanceRuben J Colman, Tomoyuki Mizuno, Keizo Fukushima, et al.
The American Journal of Gastroenterology|September 3, 2009
Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's diseaseJoel R Rosh, Trudy Lerer, James Markowitz, et al.
Inflammatory Bowel Diseases|July 29, 2015
Can You Teach a Teen New Tricks? Problem Solving Skills Training Improves Oral Medication Adherence in Pediatric Patients with Inflammatory Bowel Disease Participating in a Randomized TrialRachel N Greenley, Amitha P Gumidyala, Eve Nguyen, et al.
The American Journal of Gastroenterology|May 7, 2019
Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn's DiseaseJing Wu, David M Lubman, Subra Kugathasan, et al.
Genes and Immunity|January 30, 2019
Prioritizing Crohn's disease genes by integrating association signals with gene expression implicates monocyte subsetsKyle Gettler, Mamta Giri, Ephraim Kenigsberg, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Inflammatory Bowel Diseases|February 21, 2018
Moving On: Transition Readiness in Adolescents and Young Adults With IBDAmitha Prasad Gumidyala, Rachel N Greenley, Jill M Plevinsky, et al.
Inflammatory Bowel Diseases|September 18, 2020
Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's DiseaseRuben J Colman, Yi-Ting Tsai, Kimberly Jackson, et al.
Clinical Pharmacology and Therapeutics|December 23, 2020
Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's DiseaseYe Xiong, Tomoyuki Mizuno, Ruben Colman, et al.
Journal of Pediatric Gastroenterology and Nutrition|June 22, 2023
Exome Sequencing Implicates DGKZ , ESRRA , and GXYLT1 for Modulating Granuloma Formation in Crohn DiseaseR Alan Harris, Allyson H Bush, Todd N Eagar, et al.
Alimentary Pharmacology & Therapeutics|December 22, 2021
Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's diseaseRuben J Colman, Ye Xiong, Tomoyuki Mizuno, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2022
Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearanceRuben J Colman, Tomoyuki Mizuno, Keizo Fukushima, et al.
The American Journal of Gastroenterology|September 3, 2009
Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's diseaseJoel R Rosh, Trudy Lerer, James Markowitz, et al.
Inflammatory Bowel Diseases|July 29, 2015
Can You Teach a Teen New Tricks? Problem Solving Skills Training Improves Oral Medication Adherence in Pediatric Patients with Inflammatory Bowel Disease Participating in a Randomized TrialRachel N Greenley, Amitha P Gumidyala, Eve Nguyen, et al.
The American Journal of Gastroenterology|May 7, 2019
Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn's DiseaseJing Wu, David M Lubman, Subra Kugathasan, et al.
Genes and Immunity|January 30, 2019
Prioritizing Crohn's disease genes by integrating association signals with gene expression implicates monocyte subsetsKyle Gettler, Mamta Giri, Ephraim Kenigsberg, et al.
Pageof 4